Trials / Completed
CompletedNCT01978496
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,334 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | matching placebo |
| DRUG | Eletriptan 20 mg | 20mg oral |
| DRUG | Eletriptan 40 mg | 40mg oral |
| DRUG | Eletriptan 80 mg | 80mg oral |
Timeline
- Start date
- 1996-07-01
- Primary completion
- 1997-12-01
- Completion
- 1997-12-01
- First posted
- 2013-11-07
- Last updated
- 2021-01-28
Source: ClinicalTrials.gov record NCT01978496. Inclusion in this directory is not an endorsement.